JPRN-UMIN000012293
Completed
Phase 2
eoadjuvant radiation therapy concurrent with S-1 followed by systemic Gemcitabine therapy for Borderline resectable pancreatic cancer patients; A phase2 study - A phase2 study of neoadjuvant S1+RT followed by systemic Gem therapy for Borderline resectable pancreatic cancer patients
Hokkaido Pancreatic Cancer Study Group (HOPS)0 sites45 target enrollmentNovember 15, 2013
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Hokkaido Pancreatic Cancer Study Group (HOPS)
- Enrollment
- 45
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) treatment history of a pancreatic cancer (chemotherapy, radiotherapy, surgical) 2\) treatment history of other malignant tumors (chemotherapy, radiotherapy) 3\) Patients who can' t receive neither iodic drug because of drug allergy 4\) Including in an exposure field is impossible with contrast enhanced CT 5\) Massive pleural or abdominal effusion 6\) Pleural membranes and peritoneum sowing are proved by cytological diagnosis 7\) Existence of tumor exposure with CT or Endoscope 8\) Hemorrhagic peptic ulcer 9\) Watery diarrhea 10\) Regular use of frucitocin, fenitoin or warfarin 11\) Lung fibrosis or intestinal pneumonia, and anamnesis or imaging findings 12\) Severe infection 13\) Serious complications (e.g. heart failure, hepatic failure, intestinal paralysis, intestinal obstruction) 14\) Uncontrolled diabetes 15\) Simultaneous or metachronous (within 3 years) double cancers 16\) Patients requiring systemic steroids medication 17\) Severe mental illness 18\) Severe drug hypersensitivity 19\) Males that are currently attempting to produce a pregnancy 20\) Pregnant females, possibly pregnant females, females wishing to become pregnant 21\) Patients seems inadequate for this study by investigators
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
eoadjuvant radiation therapy concurrent with S-1 followed by systemic S-1/Gemcitabine therapy for Borderline resectable pancreatic cancer patients; A pilot studypancreatic cancerJPRN-UMIN000008888Department of Surgical Oncology and Gastroenterological Surgery, Sapporo Medical University Hospital30
Active, not recruiting
Not Applicable
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 9.1Level: LLTClassification code 10006153Term: Brain tumorEUCTR2008-003003-31-NLEORTC Headquarters108
Active, not recruiting
Not Applicable
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 9.1Level: LLTClassification code 10006153Term: Brain tumorEUCTR2008-003003-31-ATEORTC Headquarters108
Active, not recruiting
Not Applicable
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter a randomized multicenter, open-label, Phase II study. - NDpatients with newly diagnosed glioblastoma without methylation of the MGMT gene promotorMedDRA version: 12.0Level: LLTClassification code 10018336Term: GlioblastomaEUCTR2008-003003-31-ITE.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER108
Active, not recruiting
Not Applicable
Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a randomized multicenter, open-label, Phase II studypatients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoterMedDRA version: 13.1Level: LLTClassification code 10006153Term: Brain tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003003-31-DEEORTC Headquarters108